J&J to pay $158M to settle Texas Medicaid fraud case
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and its subsidiary Janssen have agreed to pay $158 million to settle charges by prosecutors in Texas that the firms had committed fraud against the state's Medicaid programme by promoting off-label uses of the schizophrenia and bipolar drug Risperdal (risperidone), specifically for use in children and the elderly.